NEOK Bio, a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, announced that it has emerged from stealth mode with $75 million in Series A financing. The company's principal investor is ABL Bio, a leading Korean biotech company and a proven leader in antibody engineering. The funding will be used to advance two bispecific ADC programs into the clinic. The company aims to be a leading bispecific ADC company in the U.S.

NEOK Bio is a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) that are designed to improve outcomes for cancer patients. NEOK is rapidly advancing bispecific ADCs which represent a cutting-edge advancement, leveraging bispecific antibodies that target two complimentary antigens, potentially improving safety while enhancing the efficacy of ADCs in a wider range of tumors. Backed by ABL Bio, Inc., a proven leader in antibody engineering, NEOK plans to initiate clinical studies for its two lead bispecific ADC candidates in solid tumor indications in mid-2026.